Oral fumaric acid esters for psoriasis (Q24187957)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

1 reference

title

Oral fumaric acid esters for psoriasis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Rachel Abbott

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Mark Kelson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

7

Vincent Piguet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

John R Ingram

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Timothy Pickles

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Andrea Bauer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

10 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

CD010497

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

Fumaric Acid Therapy for Psoriatic Arthritis. A Randomized, Double-blind, Placebo-controlled Study

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Addition of an oral histamine antagonist to reduce adverse events associated with fumaric acid esters in the treatment of psoriasis: a randomized double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

The role of drugs in the induction and/or exacerbation of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Dimethylfumarate for psoriasis: Pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Fumaric acid esters in the treatment of psoriasis: an Italian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Psoriasis in Australian twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Clearance of severe psoriasis after allogenic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Psoriasis has a major secondary impact on the lives of family members and partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Pathogenesis and clinical features of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Angiogenesis drives psoriasis pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Incidence and risk factors for psoriasis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Interventions for hidradenitis suppurativa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

The psychosocial burden of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Current and future management of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Dimethylfumarate for psoriasis: more than a dietary curiosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Global epidemiology of psoriasis: a systematic review of incidence and prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Psoriasis and its management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Oral fumaric acid esters for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Regulated genes in psoriatic skin during treatment with fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010497.PUB2

Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference

21 January 2018

1 reference

12 December 2020

A systematic review of treatments for severe psoriasis

1 reference

12 December 2020

1 reference

12 December 2020

Psoriasis: epidemiology, clinical features, and quality of life

1 reference

12 December 2020

Classification criteria for psoriatic arthritis: development of new criteria from a large international study

1 reference

12 December 2020

Fumaric acid esters for severe psoriasis: the Leicestershire experience

1 reference

12 December 2020

The Role of Streptococcal Infection in the Initiation of Guttate Psoriasis

1 reference

12 December 2020

Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression

1 reference

12 December 2020

Fumaric acid and its derivatives in the treatment of psoriasis vulgaris: our experience in forty-one patients.

1 reference

12 December 2020

Methods of Outcomes Measurement in Nail Psoriasis

1 reference

12 December 2020

Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial

1 reference

12 December 2020

Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study

1 reference

12 December 2020

Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester.

1 reference

12 December 2020

Clinical Effectiveness of Fumaric Acid Esters (Fumaderm) in Psoriasis: A Systematic Review of Literature

1 reference

12 December 2020

Meta-analysis in medical research: strong encouragement for higher quality in individual research efforts

1 reference

12 December 2020

Epidermal T lymphocytes and HLA-DR expression in psoriasis

1 reference

12 December 2020

Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients

1 reference

12 December 2020

10.1002/14651858.CD010497.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4896882

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

OpenCitations bibliographic resource ID

22 February 2020

4896882

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26258748%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

26258748

1 reference